You are here: Industry Insights > mRNA

News List

Sanofi to Acquire Translate Bio for $3.2B contractpharma
August 05, 2021
Upgrades drug formulation capabilities and accelerates development of licensed programs in vaccines and potential to explore other therapeutic areas.
Sanofi to acquire mRNA therapies developer Translate Bio for $3.2bn pharmaceutical-technology
August 04, 2021
Sanofi has signed a definitive agreement to acquire 100% outstanding shares of a messenger RNA (mRNA) therapies company, Translate Bio, for a total equity value of nearly $3.2bn, or $38 per share in cash.
Sanofi offers to buy U.S. mRNA partner Translate Bio firstwordpharma
August 03, 2021
Two sources familiar with the situation said Monday that Sanofi has offered to buy Translate Bio as the French drugmaker bets on next-generation mRNA technology following setbacks in the COVID-19 vaccine race, as reported in This is Money.
Vaxzevria and mRNA COVID-19 Vaccines Show Similar Safety Profiles americanpharmaceuticalreview
July 29, 2021
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with ...
BioNTech to develop a mRNA-based malaria vaccine pharmatimes
July 28, 2021
BioNTech has announced that the launch of a new project aimed a developing a ‘highly effective’ mRNA-based malaria vaccine candidate.
BioNTech Update on Sustainable Solutions to Infectious Disease in Africa americanpharmaceuticalreview
July 28, 2021
BioNTech SE announced the launch of its Malaria project, which aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.
eTheRNA immunotherapies joins forces with Ghent University europeanpharmaceuticalreview
July 26, 2021
eTheRNA has announced a collaboration and license agreement with renowned Belgian research institution, Ghent University.
China’s Kangtai Biological Partners With Startup to Develop mRNA Vaccines firstwordpharma
July 20, 2021
Kangtai Biological Products said it plans to work with a biotech startup to develop vaccines based on mRNA technology, as reported Yicai Global on Monday.
COVID-19 vaccine market set to reach $19.5 bn by 2026: GlobalData expresspharma
July 15, 2021
COVID-19 vaccines based on mRNA technology dominate the 7MM in 2021 with a market share of 95.4 per cent and $9.5 billion in sales for Pfizer/BioNTech and $3.5 billion for Moderna.
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms prnasia
July 12, 2021
I-Mab announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page